# US 2009/0269337 A1 · Compositions and methods for treating diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269337 A1
- Document ID: US20090269337A1
- Status: Published application
- Kind: A1
- Application number: 12/420,212
- Filed: 2009-04-08
- Published: 2009-10-29
- Earliest claimed: 2002-06-07
- Assignees: Waratah Pharmaceuticals, Inc.
- Inventors: Stephen J. Brand; Antonio Cruz
- Web page: https://patentgrep.com/patent/US20090269337A1

## CPC

- A61K 38/2207: {Gastrins; Cholecystokinins [CCK]}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/21: Interferons {[IFN]}
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.

## Claims

### Claim at position 1

-77. (canceled)

### Claim 78

A pharmaceutical composition comprising an agent for suppressing an immune response and a gastrin/CCK receptor ligand in the absence of a EGF receptor ligand, wherein the agent for suppressing immune response is at least one selected from the group consisting of: hul 124; BTI-322; allotrap-HLA-B270; OKT4A; Enlimomab; ABX-CBL; OKT3; ATGAM; basiliximab; daclizumab; antithymocyte immunoglobulin; ISAtx247; Medi-500; Medi-507; Alefacept; efalizumab; infliximab; and an interferon and the gastrin/CCK receptor ligand is gastrin 17(Leu 15).

### Claim 79

A method of treating a diabetic subject comprising administering to said subject an agent that increases islet neogenesis and an agent that suppresses an immune response in the absence of a EGF receptor ligand, wherein said agent that increases islet neogenesis is gastrin 17(Leu 15) and wherein the agent for suppressing immune response is at least one selected from the group consisting of: hul 124; BTI-322; allotrap-HLA-B270; OKT4A; Enlimomab; ABX-CBL; OKT3; ATGAM; basiliximab; daclizumab; antithymocyte immunoglobulin; ISAtx247; Medi-500; Medi-507; Alefacept; efalizumab; infliximab; and an interferon and the gastrin/CCK receptor ligand is gastrin 17(Leu 15).

### Claim 80 (depends on 79)

The method according to claim 79, wherein said agent that increases islet neogenesis and said agent that suppresses an immune response are administered sequentially.

### Claim 81 (depends on 80)

The method according to claim 80, wherein the subject is a human.

### Claim 82 (depends on 80)

The method according to claim 80, wherein the diabetic subject has recent onset diabetes.
